Gritstone bio Future Growth

Future criteria checks 2/6

Gritstone bio's earnings are forecast to decline at 8.1% per annum while its annual revenue is expected to grow at 55.7% per year. EPS is expected to grow by 6.2% per annum.

Key information

-8.1%

Earnings growth rate

6.2%

EPS growth rate

Biotechs earnings growth28.3%
Revenue growth rate55.7%
Future return on equityn/a
Analyst coverage

Low

Last updated11 Oct 2024

Recent future growth updates

Recent updates

We Think Some Shareholders May Hesitate To Increase Gritstone bio, Inc.'s (NASDAQ:GRTS) CEO Compensation

Jun 11
We Think Some Shareholders May Hesitate To Increase Gritstone bio, Inc.'s (NASDAQ:GRTS) CEO Compensation

Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering

Apr 07

Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%

Aug 14
Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%

Gritstone bio: Early Data For SLATE Candidate Sets Up 2023 Catalyst

Sep 26

Gritstone reaches six-month high on publication of data for cancer vaccine

Aug 16

Gritstone bio announces $80M credit facility

Jul 21

Is Gritstone bio (NASDAQ:GRTS) In A Good Position To Invest In Growth?

Jul 07
Is Gritstone bio (NASDAQ:GRTS) In A Good Position To Invest In Growth?

Gritstone bio: Potential To Advance Colorectal Cancer Treatment

Jul 05

Gritstone bio: Investing In A Premium mRNA Technology At A Discounted Valuation

Jun 14

Some Analysts Just Cut Their Gritstone bio, Inc. (NASDAQ:GRTS) Estimates

Mar 17
Some Analysts Just Cut Their Gritstone bio, Inc. (NASDAQ:GRTS) Estimates

We're Not Very Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Rate

Mar 05
We're Not Very Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Rate

Gritstone: Why The Stock Fell On Positive Data

Jan 18

Gritstone bio (NASDAQ:GRTS) Is In A Strong Position To Grow Its Business

Nov 23
Gritstone bio (NASDAQ:GRTS) Is In A Strong Position To Grow Its Business

Gritstone Poised To Dominate mRNA Market

Nov 08

Earnings and Revenue Growth Forecasts

NasdaqGS:GRTS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202616-176-146-1043
12/31/20258-136-129-925
12/31/20249-115-118-855
6/30/202415-133-112-111N/A
3/31/202416-145-118-115N/A
12/31/202316-138-126-122N/A
9/30/202310-139-138-133N/A
6/30/202312-130-133-127N/A
3/31/202315-125-128-123N/A
12/31/202220-120-122-116N/A
9/30/202219-118-115-109N/A
6/30/202218-116-105-98N/A
3/31/202216-112-101-95N/A
12/31/202148-75-56-51N/A
9/30/202146-72-57-52N/A
6/30/202145-70-61-57N/A
3/31/202142-71-58-55N/A
12/31/20204-105-93-89N/A
9/30/20204-106-95-86N/A
6/30/20204-107-105-91N/A
3/31/20204-103-104-89N/A
12/31/20194-94-101-85N/A
9/30/20195-84-88-76N/A
6/30/20194-75-56-49N/A
3/31/20193-69-49-42N/A
12/31/20181-65-44-38N/A
9/30/20180-65-46-40N/A
6/30/2018N/A-56-60-49N/A
3/31/2018N/A-47N/A-44N/A
12/31/2017N/A-41N/A-35N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GRTS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GRTS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GRTS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GRTS's revenue (55.7% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: GRTS's revenue (55.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if GRTS's Return on Equity is forecast to be high in 3 years time


Discover growth companies